AMENDMENT TO
4D MOLECULAR THERAPEUTICS, INC.
2025 EMPLOYMENT INDUCEMENT AWARD PLAN
This amendment (“Amendment”) to the 2025 Employment Inducement Award Plan (the “Inducement Plan”) of 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”) is made pursuant to Section 11.4 of the Plan, effective as of January 23, 2026.
WITNESSETH THAT:
WHEREAS, the Company presently maintains the Inducement Plan for the benefit of its employees;
WHEREAS, pursuant to Section 11.4 of the Plan, the Board of Directors of the Company (the “Board”) may amend, suspend, or terminate the Plan at any time;
WHEREAS, the Plan is exempt from Nasdaq rules requiring stockholder approval of “equity compensation plans” pursuant to the Nasdaq Rule 5635(c)(4) exemption for “employment inducement awards,” and, accordingly, the Amendment shall not be submitted to the Company’s stockholders for their approval; and
WHEREAS, the Board believes it is in the best interests of the Company to amend the Inducement Plan as set forth in this Amendment.
NOW THEREFORE, the Plan is hereby amended as follows:
“Number of Shares. Subject to adjustment under Article IX and the terms of this Article V, Awards may be made under the Plan covering up to 1,500,000 Shares. Shares issued or delivered under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.”
* * *